Skip to main content
Premium Trial:

Request an Annual Quote

DiaCarta Raises $45M in Series B Funding

NEW YORK (GenomeWeb) – DiaCarta said today that it has completed a Series B funding round, raising a total of $45 million. The second closing was led by Fortune Fountain Capital and included an investment from Good Health Capital.

DiaCarta Founder and CEO Aiguo Zhang said in a statement that the financing will support continued development of the company’s core XNA technology platform, and will support work to expand its diagnostic products for non-invasive early detection and monitoring of cancers. This will include establishing global clinical study programs in various areas, the commercial launch of the firm's liquid biopsy ColoScape assay for the detection of colorectal cancer, and the inception of new product development pipelines.

Funds raised will also help support future marketing applications to the US and China Food and Drug Administrations for relevant tests, Zhang said.


The Scan

Guidelines for Ancient DNA Work

More than two dozen researchers have developed new ethical guidelines for conducting ancient DNA research, which they present in Nature.

And Cleared

A UK regulator has cleared former UK Prime Minister David Cameron in concerns he should have registered as a consultant-lobbyist for his work with Illumina, according to the Financial Times.

Suit Over Allegations

The Boston Globe reports that David Sabatini, who was placed on leave from MIT after allegations of sexual harassment, is suing his accuser, the Whitehead Institute, and the institute's director.

Nature Papers on Esophageal Cancer, Origin of Modern Horses, Exome Sequencing of UK Biobank Participants

In Nature this week: genetic and environmental influences of esophageal cancer, domestic horse origin traced to Western Eurasian steppes, and more.